137 related articles for article (PubMed ID: 21590366)
1. Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
Kratz F; Fichtner I; Graeser R
Invest New Drugs; 2012 Aug; 30(4):1743-9. PubMed ID: 21590366
[No Abstract] [Full Text] [Related]
2. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
3. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Graeser R; Esser N; Unger H; Fichtner I; Zhu A; Unger C; Kratz F
Invest New Drugs; 2010 Feb; 28(1):14-9. PubMed ID: 19148580
[TBL] [Abstract][Full Text] [Related]
4. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
Kratz F
Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
[TBL] [Abstract][Full Text] [Related]
5. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
7. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
8. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.
Boven E; Hendriks HR; Erkelens CA; Pinedo HM
Br J Cancer; 1992 Dec; 66(6):1044-7. PubMed ID: 1457343
[TBL] [Abstract][Full Text] [Related]
10. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
12.
Cornillie J; Wozniak A; Pokreisz P; Casazza A; Vreys L; Wellens J; Vanleeuw U; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
Mol Cancer Ther; 2017 Aug; 16(8):1566-1575. PubMed ID: 28566438
[TBL] [Abstract][Full Text] [Related]
13. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
14. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
15. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
[TBL] [Abstract][Full Text] [Related]
16. Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Sanchez E; Li M; Wang C; Nichols CM; Li J; Chen H; Berenson JR
Clin Cancer Res; 2012 Jul; 18(14):3856-67. PubMed ID: 22619306
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
[TBL] [Abstract][Full Text] [Related]
18. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
19. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
20. Inverted chemistry--from drug to prodrug.
Renner M
Trends Mol Med; 2001 Mar; 7(3):100. PubMed ID: 11286768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
